Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under the ticker DECA, is the product of a de-SPAC business combination involving Denali Capital Acquisition Corp., a healthcare-focused blank-check company that completed its IPO in 2022. Semnur is a clinical-stage pharmaceutical company developing treatments for spinal pain conditions, including its lead asset targeting lumbar radiculopathy. The company filed an 8-K with the SEC on August 22, 2025, under accession number 0001213900-25-079504, reporting a material corporate event following the completion of its merger. DECA currently trades as the combined post-merger entity in the healthcare and biopharmaceutical sector. Visit SpacDesk and sign up for full data, filings history, and real-time alerts on DECA and hundreds of other SPAC and de-SPAC transactions.